Use of carvedilol in the treatment of heart failure
Andrew J.S. Coats
Abstract
Andrew J.S. Coats
Abstract
Carvedilol is a multiple action, non-specific, adrenergic beta-blocker, licensed for the treatment of mild, moderate and severe chronic heart failure. This article considers the evidence for using beta-blockers in general, and carvedilol in particular, in the treatment of heart failure. Evidence suggests that carvedilol should be considered as an alternative first-line initiation therapy.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Carvedilol is a multiple action, non-specific, adrenergic beta-blocker, licensed for the treatment of mild, moderate and severe chronic heart failure. This article considers the evidence for using beta-blockers in general, and carvedilol in particular, in the treatment of heart failure. Evidence suggests that carvedilol should be considered as an alternative first-line initiation therapy.
Key concepts: Carvedilol, Medicine, Heart failure, Cardiology, BETA (programming language), Adrenergic beta-Antagonists, Beta blocker, Internal medicine